Strs Ohio Has $4.22 Million Stake in United Therapeutics Corporation $UTHR

Strs Ohio increased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 847.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,062 shares of the biotechnology company’s stock after acquiring an additional 9,000 shares during the period. Strs Ohio’s holdings in United Therapeutics were worth $4,218,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Emerald Mutual Fund Advisers Trust grew its holdings in shares of United Therapeutics by 112.2% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 5,474 shares of the biotechnology company’s stock worth $2,295,000 after purchasing an additional 2,894 shares during the last quarter. Rakuten Investment Management Inc. bought a new stake in United Therapeutics during the 3rd quarter worth approximately $1,823,000. Seizert Capital Partners LLC increased its position in United Therapeutics by 17.1% in the 3rd quarter. Seizert Capital Partners LLC now owns 146,991 shares of the biotechnology company’s stock valued at $61,620,000 after acquiring an additional 21,450 shares during the period. Root Financial Partners LLC bought a new position in shares of United Therapeutics during the third quarter valued at $51,000. Finally, Allstate Corp bought a new stake in shares of United Therapeutics in the third quarter worth $614,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. UBS Group lifted their target price on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $473.36 on Tuesday. The business has a 50-day simple moving average of $487.69 and a 200 day simple moving average of $416.98. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The firm has a market capitalization of $20.38 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 2.51 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter last year, the firm posted $6.39 earnings per share. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $429.25, for a total transaction of $9,658,125.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 536,864 shares of company stock valued at $255,191,362 over the last 90 days. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.